DMA
Actually, if would not have cost GSK much to move Relenza to the hovione device and would have overcame the difficult usage problem.
- Forums
- ASX - By Stock
- BTA
- research data sankyo tjw
research data sankyo tjw, page-2
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)